The biotech betting gene-silencing can prevent strokes goes public #Biotech #GeneSilencing

ADARx’s planned IPO could signal growing confidence in complement therapeutic, with a CFB-targeting siRNA advancing into AMD geographic atrophy. Could durable complement suppression be the next step for AMD? #AMD #Complement #siRNA #GeneSilencing buff.ly/K4O3O33